5/16/2012 7:22:29 AM
After spending nearly $15 billion on overseas acquisitions in less than two years, Japan's top drug maker Takeda Pharmaceutical Co. is not ruling out further deals as it looks to overcome patent expiries and cement its position as a global industry player. "We will be looking for those things that are a very good fit with what we have already put in place," Anna Protopapas, a corporate officer at Takeda who oversees the company's global M&A functions, said in a recent interview. Protopapas helped to engineer Takeda's $13.7 billion purchase of Swiss drug maker Nycomed last year--the second-biggest foreign purchase ever by a Japanese firm--and led a $800 million all-cash deal to buy Philadelphia-based URL Inc. that was announced in April.
comments powered by